George Rieveschl, Inventor of Benadryl, Dies
CINCINNATIUniversity of Cincinnati (UC) alumnus and engineering professor emeritus George Rieveschl, PhD, known for inventing Benadryl, the worlds first effective antihistamine, died today at Christ Hospital, Cincinnati. He was 91.
A long-time supporter of the
Dr. Rieveschl was also the founding chairman of the University Foundation Board of Trustees.
Rieveschl was a chemistry professor at UC when he invented Benadryl.
He found to this surprise that a two-part compound he was originally testing to improve muscle-relaxing medications dramatically blocked histamine, the naturally released chemical that narrows air passages in the lungs and causes inflammation.
This breakthrough led, in 1946, to Benadryls becoming the first FDA-approved prescription antihistamine. First produced by Parke, Davis and Company, the drug is now distributed over-the-counter by the Parke-Davis division of Pfizer.
A 1937 alumnus of UC, Dr. Rieveschl spent 26 years working in the chemical industry as both a scientist and a consultant before returning to UC in 1970.
He is survived by his wife, Ellen, and two sons.
George Rieveschl, PhD
Jane Henney, MD, presents Benadryl inventor George Rieveschl, PhD, with a city proclamation noting May 16 as "60 Years of Benadryl" day.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.